Abstract
The standard therapy for locally advanced gastric cancer (GC) is a combination of radical gastrectomy and pre- and/or post-operative chemotherapy. Gastrectomy sometimes induces severe body weight loss (BWL) which has been reported as a risk factor for incompliance with an adjuvant chemotherapy. However, there are no reports describing the risk factors for postoperative BWL using data from a prospective clinical trial. The phase III trial (JCOG1001), comparing bursectomy and non-bursectomy in resectable advanced GC treatment, registered a total of 1204 patients between June 2010 and March 2015.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
